Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345705 | 0.86 | SORD (0.41) | — | |
| SCHEMBL345160 | 0.78 | MEN1 (0.36) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL346096 | 0.75 | CHRM4 (0.43) | KMT2APKM | |
| SCHEMBL345098 | 0.74 | SCD (0.35) | MEN1KMT2AGFER | |
| SCHEMBL1267034 | 0.68 | MEN1 (0.52) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL345397 | 0.67 | MEN1 (0.38) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL16162195 | 0.67 | MEN1 (0.51) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL16269780 | 0.66 | MEN1 (0.52) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL15662150 | 0.64 | MEN1 (0.47) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL2125396 | 0.63 | MEN1 (0.55) | MEN1KMT2AGFERPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | MEN1 812/4885KMT2A 2849/4885GFER 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.